Skip to content

Breast Cancer

US Focus Meeting 2026


📍 Sheraton Grand Nashville Downtown, 623 Union St, Nashville, TN 37219

🗓️ April 24 - 25, 2026


Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the Breast Cancer Focus Meeting 2026, to be held on April 24 - 25, 2026.

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Breast Cancer research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of Breast Cancer US Focus Meeting 2026:

KJ

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York City, NY


VK

Virginia Kaklamani, MD
UT Health, San Antonio, TX


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
cristina.anton@md-education.com

Agenda & Faculty

April 10, 2026 | Day 1  

07:00 AM
08:00 AM
08:45 AM
Registration Opens
Industry Supported Independent Expert Discussion
Coffee Break

Session I: Advances in HER2-Positive Breast Cancer
Moderated by:

VK

Virginia Kaklamani, MD
UT Health, San Antonio, TX

09:05 AM
Defining the New Standard of Care for HER2-Positive Metastatic Breast Cancer
Reshma-Mahtani
Reshma L. Mahtani, MD
Baptist Health Wellness and Medical Complex, Plantation, FL
09:25 AM
Optimizing Treatment of Early-Stage HER2-Positive Breast Cancer
Ian-Krop-1
Ian Krop, MD
Yale School of Medicine, New Haven, CT
09:45 AM
Management of Brain Metastases in Metastatic Breast Cancer

AB

Andrew Brenner, MD
UT Health, San Antonio, TX
10:05 AM
10:25 AM
Panel Discussion
Coffee Break

Session II: Optimizing Treatment of Triple-Negative Breast Cancer
Moderated by:

KJ

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York City, NY

10:45 AM
Novel Endocrine Therapies
Sarah-Sammons-1
Sarah Sammons, MD
Dana-Farber Cancer Institute, Boston, MA
11:05 AM
(Neo)Adjuvant Therapy for ER-Positive Breast Cancer
Cynthia-Ma-1
Cynthia Ma, MD
Washington University School of Medicine,
St. Louis, MO
11:25 AM
Novel Targeted Agents for ER+ Metastatic Breast Cancer

SW

Seth Wander, MD
Massachusetts General Hospital, Boston, MA
11:45 AM
12:05 PM
12:55 PM
Panel Discussion
Lunch Break + Faculty and Fellow Photo
Industry Supported Independent Expert Discussion

Session III: Advances in Hormone Receptor-Positive Breast Cancer
Moderated by:

KJ

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York City, NY

01:40 PM
Defining the New Standard of Care for Metastatic TNBC
Neil-Iyengar
Neil Iyengar, MD
Emory Winship Cancer Institute, Atlanta, GA
02:00 PM
Optimizing Treatment for Early-Stage TNBC

YA

Yara Abdou, MD
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
02:20 PM
The Future of Immunotherapy

WM

Wassim Mchayleh, MD
Advent Health Cancer Institute, Orlando, FL
02:40 PM
03:00 PM
03:20 PM
Panel Discussion
Coffee Break
Industry Supported Independent Expert Discussion

Session IV: Innovations in Breast Surgery and Radiation
Moderated by:

VK

Virginia Kaklamani, MD
UT Health, San Antonio, TX

04:05 PM

Endoscopic Breast Surgery: Is It the Future?

HH

Hong Hu, MD
Shenzhen People’s Hospital, Guangdong
Province, China
04:25 PM

Optimizing Axillary Management for ER+ Breast Cancer: Is Less More?

Alastair-Thompson-1
Alastair Thompson, MD
Baylor College of Medicine, Houston, TX
05:05 PM
05:25 PM
Panel Discussion
Adjourn

Saturday, April 25, 2026 | Day 2

07:00 AM
08:00 AM
08:45 AM
Registration Opens
Industry Supported Independent Expert Discussion
Coffee Break

Session V: Challenging Metastatic Disease Scenarios
Moderated by:

KJ

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York City, NY

09:05 AM

Can We Cure Oligometastatic Disease?

Pavani-Chalasani
Pavani Chalasani, MD
The George Washington University,
Washington, DC
09:25 AM

Treatment of Leptomeningeal Disease

AB

Andrew Brenner, MD
UT Health, San Antonio, TX
09:45 AM

Treating for Molecular Progression

Lajos-Pusztai
Lajos Pusztai, MD
Yale School of Medicine, New Haven, CT
10:05 AM
10:25 AM
Panel Discussion
Coffee Break

Session VI: Emerging Therapeutics and Special Perspectives
Moderated by:

VK

Virginia Kaklamani, MD
UT Health, San Antonio, TX

10:45 AM

ADCs: Present and Future for “HER2- Negative” Breast Cancer

KJ

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center New York, NY
11:05 AM

Role of Radioligand Imaging and Therapy in Breast Cancer

Gary-Ulaner
Gary Ulaner, MD
Hoag Family Cancer Institute, Irvine, CA
11:25 AM

Lobular Breast Cancers: Should We Treat Them Distinctly?

sherry-shen
Sherry Shen, MD
Memorial Sloan Kettering Cancer Center, New York, NY
11:45 AM

Novel Techniques in Breast Radiation

Richard-Zellars
Richard Zellars, MD
Indiana University School of Medicine,
Indianapolis, IN
12:05 PM
12:25 PM
01:15 PM
Panel Discussion
Lunch Break
Industry Supported Independent Expert Discussion

Session VII: Breast Cancer Prevention and Risk Management
Moderated by:

KJ

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York City, NY

02:00 PM

Updates on Breast Cancer Prevention

VK

Virginia Kaklamani, MD
UT Health, San Antonio, TX
02:20 PM

Management of Genetically High-Risk Patients

MR

Mark Robson, MD
Memorial Sloan Kettering Cancer Center, New York, NY
02:40 PM

Role of Exercise and GLP-1 Agonists in Breast Cancer

Saba-Shaikh-1
Saba Shaikh, MD
UT Health, San Antonio, TX
03:00 PM
03:20 PM
03:40 PM
Panel Discussion
Coffee Break
Industry Supported Independent Expert Discussion

Session VIII: Survivorship, Toxicity Management, and Patient
Moderated by:

VK

Virginia Kaklamani, MD
UT Health, San Antonio, TX

04:25 PM

Oncofertility

Kate-Lathrop
Kate Lathrop, MD
UT Health, San Antonio, TX
04:45 PM

irAEs and Their Management

Shipra-Gandhi
Shipra Gandhi, MD
Emory Winship Cancer Institute, Atlanta, GA
05:05 PM

Beyond Survival: Optimizing Endpoints in Contemporary Cancer Trials

YS

Yu Shyr, MD
Vanderbilt University Medical Center,
Nashville, TN
05:25 PM
05:45 PM
Panel Discussion
Adjourn

Cristina Anton
Senior Project Manager

How long has Cristina Anton been in the business?

Cristina Anton has been with MD Education since 2022.

About Cristina Anton

As a Senior Project Manager at MD Education’s Wigan office since 2022, I organise international medical conferences with a focus on breast cancer and inflammatory bowel disease (IBD). Originally from Romania, I have been based in the UK since 2015. My diverse background across sectors helps me deliver high-quality, impactful educational programs. I’m committed to excellence and continuous growth.

Cristina-Anton